Key result
Advanced therapies improve survival and quality of life in refractory advanced heart failure.
Why the study?
Advanced heart failure is refractory to maximal medical, device, and surgical treatments, necessitating evaluation of criteria and outcomes for mechanical circulatory support and cardiac transplant.
Supports evaluation for advanced therapies in refractory HF; leaves open need for higher-level evidence to guide selection.
Advanced heart failure (AHF) is the stage of heart failure (HF) refractory to maximal medical treatment, cardiac devices (CRT - cardiac resynchronization, ICD - implantable defibrillator) and surgical treatment. AHF has become of interest through the experience and favorable results of treatment by mechanical circulatory support (MCS) and cardiac transplant (CT). The article reviews the criteria for defining the AHF (2018 ESC statement), natural history and prognosis outside the advanced treatment forms. Evaluation of risk and prognostic factors is required before the decision of advanced therapy: clinical factors (HF severity and reduction of cardiorespiratory functional capacity), RV function, biological markers and elements of organ dysfunction, as well as reduction of tolerance to conventional medication. Finally, the principles of treatment and the results of mechanical circulatory support and cardiac transplant are presented.
No takes yet. Share an insight, caveat, or question.
Leonida Gherasim (2019) conducted a review in Advanced Heart Failure. Advanced heart failure management (mechanical circulatory support and cardiac transplantation) was evaluated. Advanced therapies such as mechanical circulatory support and cardiac transplantation provide significant survival and quality of life benefits for properly selected patients with advanced heart failure refractory to optimal medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: